New Drug MS 001 May Preserve Muscle and Boost Fat Loss Alongside GLP-1 Therapy

The way obesity drugs are judged may be about to change. For years, success meant a lower number on the scale. But researchers and clinicians increasingly recognize that losing muscle alongside fat undermines long-term health — particularly as we age. MetaShape Pharma's new preclinical data, presented at the 2026 American Diabetes Association Scientific Sessions, puts that question front and center.

The Swiss biotech's lead candidate, MS 001, was tested in obese animal models alongside semaglutide, the active ingredient in Ozempic and Wegovy. The combination produced greater overall weight loss than semaglutide alone. More strikingly, animals receiving MS 001 showed increased muscle mass and improved treadmill endurance — outcomes rarely associated with weight-loss therapies. This suggests the drug may selectively drive fat loss while actively protecting or enhancing lean tissue.

Equally notable is the mechanism. GLP-1 drugs work primarily by suppressing appetite and slowing digestion — they help people eat less. MS 001 appears to work differently: animals lost more weight without eating any less. Instead, the drug seemed to increase energy expenditure and accelerate fat metabolism. This complementary mechanism could make it a powerful adjunct rather than a competitor to existing therapies.

The drug also appears to target two other major GLP-1 weaknesses: weight-loss plateaus and post-treatment rebound. Both are significant clinical problems that limit the long-term value of current medications. If MS 001 can mitigate these effects in humans, it could meaningfully extend the utility of GLP-1 therapy.

However, important caveats apply. All data are preclinical — derived from animal models, not humans. Animal studies frequently fail to replicate in human trials. No safety data, dosing information, or human pharmacokinetics have been published. The findings are promising and scientifically credible in framing, but human trials are necessary before any clinical conclusions can be drawn.